UA103544C2 - Кристалічна форма і цинкової солі розувастатину - Google Patents
Кристалічна форма і цинкової солі розувастатинуInfo
- Publication number
- UA103544C2 UA103544C2 UAA201201836A UAA201201836A UA103544C2 UA 103544 C2 UA103544 C2 UA 103544C2 UA A201201836 A UAA201201836 A UA A201201836A UA A201201836 A UAA201201836 A UA A201201836A UA 103544 C2 UA103544 C2 UA 103544C2
- Authority
- UA
- Ukraine
- Prior art keywords
- crystalline form
- zinc salt
- rosuvastatin zinc
- rosuvastatin
- salt
- Prior art date
Links
- KUQHZGJLQWUFPU-BGRFNVSISA-L zinc;(e,3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate Chemical class [Zn+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O KUQHZGJLQWUFPU-BGRFNVSISA-L 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960000672 rosuvastatin Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Даний винахід стосується кристалічної форми І солі розувастатину цинку (2:1), способу її одержання та її застосування як фармацевтично активного інгредієнта для лікування захворювань, пов'язаних з метаболізмом ліпідів, що включають гіперліпопротеїнемію, гіперхолестеринемію, дисліпідемію і атеросклероз.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HU2009/000064 WO2011010174A1 (en) | 2009-07-24 | 2009-07-24 | Crystalline form i rosuvastatin zinc salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA103544C2 true UA103544C2 (uk) | 2013-10-25 |
Family
ID=41258771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201201836A UA103544C2 (uk) | 2009-07-24 | 2009-07-24 | Кристалічна форма і цинкової солі розувастатину |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9023838B2 (uk) |
| EP (1) | EP2483248B1 (uk) |
| JP (1) | JP5702778B2 (uk) |
| CN (1) | CN102548971B (uk) |
| AU (1) | AU2009350099B2 (uk) |
| EA (1) | EA020944B1 (uk) |
| ES (1) | ES2598162T3 (uk) |
| HU (1) | HUE029858T2 (uk) |
| IL (1) | IL217898A0 (uk) |
| UA (1) | UA103544C2 (uk) |
| WO (1) | WO2011010174A1 (uk) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230737B1 (hu) * | 2010-11-16 | 2018-01-29 | EGIS Gyógyszergyár Nyrt | Eljárás rosuvastatin só előállítására |
| HU231036B1 (hu) * | 2013-09-30 | 2019-12-30 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008509154A (ja) * | 2004-08-06 | 2008-03-27 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なスタチン薬剤組成物および関連治療方法 |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| WO2008015563A2 (en) * | 2006-08-04 | 2008-02-07 | Glenmark Pharmaceuticals Limited | Salts of rosuvastatin and processes for their preparation |
| HU230981B1 (hu) * | 2007-10-12 | 2019-08-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin só előállítására |
| HU230637B1 (hu) * | 2007-10-12 | 2017-05-29 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin intermedierek előállítására |
| EP2389365A1 (en) * | 2009-01-15 | 2011-11-30 | Egis Gyógyszergyár Nyilvánosan Müködö | Process for the preparation of rosuvastatin salts |
-
2009
- 2009-07-24 EA EA201290051A patent/EA020944B1/ru not_active IP Right Cessation
- 2009-07-24 JP JP2012521105A patent/JP5702778B2/ja not_active Expired - Fee Related
- 2009-07-24 CN CN200980160962.0A patent/CN102548971B/zh not_active Expired - Fee Related
- 2009-07-24 UA UAA201201836A patent/UA103544C2/uk unknown
- 2009-07-24 WO PCT/HU2009/000064 patent/WO2011010174A1/en not_active Ceased
- 2009-07-24 EP EP09785765.0A patent/EP2483248B1/en active Active
- 2009-07-24 ES ES09785765.0T patent/ES2598162T3/es active Active
- 2009-07-24 US US13/383,490 patent/US9023838B2/en not_active Expired - Fee Related
- 2009-07-24 HU HUE09785765A patent/HUE029858T2/en unknown
- 2009-07-24 AU AU2009350099A patent/AU2009350099B2/en active Active
-
2012
- 2012-02-02 IL IL217898A patent/IL217898A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102548971B (zh) | 2015-09-16 |
| CN102548971A (zh) | 2012-07-04 |
| EP2483248A1 (en) | 2012-08-08 |
| HUE029858T2 (en) | 2017-04-28 |
| ES2598162T3 (es) | 2017-01-25 |
| EP2483248B1 (en) | 2016-07-20 |
| WO2011010174A8 (en) | 2012-07-05 |
| AU2009350099A1 (en) | 2012-03-08 |
| EA020944B1 (ru) | 2015-02-27 |
| US9023838B2 (en) | 2015-05-05 |
| JP2013500250A (ja) | 2013-01-07 |
| US20120178729A1 (en) | 2012-07-12 |
| JP5702778B2 (ja) | 2015-04-15 |
| EA201290051A1 (ru) | 2012-09-28 |
| WO2011010174A1 (en) | 2011-01-27 |
| AU2009350099B2 (en) | 2015-10-29 |
| IL217898A0 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY177742A (en) | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine | |
| EA202091303A3 (ru) | Композиция ингибитора jak для местного применения | |
| WO2010132999A8 (en) | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| PH12012502528A1 (en) | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| GEP201706620B (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| MX338088B (es) | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). | |
| PH12012500622A1 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| MY164864A (en) | Indenone derivative and pharmaceutical composition comprising same | |
| PH12014500065A1 (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| MY155938A (en) | Oral pharmaceutical composition | |
| HK1220386A1 (zh) | Ep4受体拮抗剂在软骨疾病的治疗中的用途 | |
| MX2012013478A (es) | Composicion para evitar perdida del cabello o estimular crecimiento del cabello. | |
| UA112423C2 (uk) | Спосіб одержання (варіанти) кристалічних форм розувастатину тба | |
| UA103544C2 (uk) | Кристалічна форма і цинкової солі розувастатину | |
| NZ611072A (en) | Method for preparing rosuvastatin salts | |
| MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| MX353991B (es) | Agonista del receptor de 5-ht4 como agente procinetico. | |
| MX2010011006A (es) | Nueva sal de un derivado de pirimidina. | |
| NZ609804A (en) | Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid | |
| HU1000616D0 (en) | Crystalline pharmaceutically active ingredient | |
| WO2012072791A3 (en) | 2-(1-phenyl-4,5,6,7-tetrahydro-1h-indazol-4-yl)ethylamine derivatives useful as sigma receptor inhibitors | |
| WO2010128346A3 (en) | Rosuvastatin manganse, copper, iron and zinc salts with high photochemical stability | |
| EP2407454A4 (en) | PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTICAL NERVE DISORDERS COMPRISING A DERIVATIVE OR SALT OF 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID AS ACTIVE INGREDIENT |